Ping An Biomedical Signs LOI To Acquire Three Oncology Technology Patents For $2M-$2.5M

Ping An Biomedical Co., Ltd. (NASDAQ:PASW) (the "Company") today announced its entry into a letter of intent with Future Biotechnology Group Co., Limited (the "Letter of Intent"), for the planned acquisition (the "Planned Acquisition") of three tumor cell-related medical technology patents covering areas including oncology diagnosis and treatment, cell detection and bioengineering, and biomarker and DNA probe technologies, for a consideration ranging from US 2 million to US 2.5 million. The Planned Acquisition shall be subject to a final acquisition agreement to be subsequently prepared and executed by the parties. The Planned Acquisition is intended to support the Company’s longer-term healthcare and biomedical R&D strategy and to establish a core intellectual property portfolio in oncology and biotechnology.

Strategic Rationale

The Company believes the Planned Acquisition is in line with its assessment of long-term structural trends in the healthcare market, particularly the growing importance of oncology-related diagnostics, research tools, and enabling biotechnologies. The Planned Acquisition is intended to advance the Company’s longer-term healthcare and biomedical strategy by establishing its position in tumor-related technology areas through targeted intellectual property. The Company intends to gradually build a healthcare technology asset reserve that can support not only ownership of core intellectual properties, but also potential pathways such as internal development, collaboration, and licensing. The Company expects this intellectual property reserve to provide foundational IP support for the subsequent commercialization and rollout of related healthcare businesses.

Expected Significance and Next Steps

Upon completion of the Planned Acquisition, the Company intends to incorporate the patents into its healthcare technology IP reserve. Management plans to evaluate appropriate pathways for further development, which may include internal research and development, collaboration with partners, and/or licensing, subject to further assessment and applicable approvals. The Company does not expect the Planned Acquisition , by itself, to generate material revenue in the near term; rather, it is intended as a foundational step to support the Company’s longer-term healthcare and biomedical initiatives.